🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 24 Chengdu 20 Changsha 18 Guangzhou 17 Shanghai 14
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158 Clear sponsor filter
Site location
Beijing24 Chengdu20 Changsha18 Guangzhou17 Shanghai14
All 51 locations
Target enrolment
to

Trials with a site in Beijing

24 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection Fraction
NCT07044700Heart Failure of Reduced Ejection Fraction (HFrEF)
Boehringer Ingelheim
Observational
5,000
Beijing
2028-01-31
Not yet open
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
NCT07789015Idiopathic Inflammatory Myopathies
Boehringer Ingelheim
Phase 3
270
Beijing, Chongqing, Dongguan, Guangzhou, Hefei, Luoyang, Nanchang, Nanjing
2026-11-09
Not yet open
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
NCT07540988Interstitial Lung Diseases
Boehringer Ingelheim
Phase 3
466
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou
2026-09-14
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087Systemic Sclerosis
Boehringer Ingelheim
Phase 3
448
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Luoyang
2026-07-27
Recruiting
A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)
NCT07366034Fibrosing Interstitial Lung Disease
Boehringer Ingelheim
Phase 3
35
Beijing, Changsha, Shanghai
2026-07-21
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)
Boehringer Ingelheim
Phase 3
390
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2026-07-10
Recruiting
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
NCT07409181Systemic Lupus Erythematosus
Boehringer Ingelheim
Phase 2
405
Beijing, Changchun, Changsha, Guangzhou, Linfen, Nanjing, Ningbo, Shanghai
2026-04-20
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Boehringer Ingelheim
Phase 3
670
Beijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2026-04-13
Recruiting
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
NCT07355296Proteinuric Kidney Diseases
Boehringer Ingelheim
Phase 2
132
Beijing, Chengdu, Guangzhou, Nanchang, Nanjing, Nanning, Shanghai, Sichuan
2026-03-23
Recruiting
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
NCT07361302Acute Ischemic Stroke
Boehringer Ingelheim
Phase 3
1,325
Anyang, Baoji, Baotou, Beijing, Cangzhou, Changchun, Changsha, Chengdu
2026-02-17
Recruiting
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
NCT07220083Focal Segmental Glomerulosclerosis
Boehringer Ingelheim
Phase 3
286
Baotou, Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Lanzhou
2026-02-16
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695Non-small Cell Lung Cancer
Boehringer Ingelheim
Phase 3
400
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan
2026-01-16
Recruiting
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Boehringer Ingelheim
Phase 3
400
Beijing, Chengdu, Guangzhou, Hangzhou, Luoyang, Macau, Nanchang, Shanghai
2025-09-13
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Boehringer Ingelheim
Phase 3
11,800
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian
2025-07-22
Recruiting
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892Bronchiectasis
Boehringer Ingelheim
Phase 3
1,755
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2025-06-09
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370Heart Failure
Boehringer Ingelheim
Phase 3
4,200
Beijing, Changchun, Changde, Changsha, Chengdu, Chenzhou, Chongqing, Dalian
2025-05-20
Recruiting
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457Metabolic Dysfunction Associated Steatohepatitis
Boehringer Ingelheim
Phase 3
1,590
Beijing, Changchun, Changsha, Changzhou Shi, Chengdu, Chongqing, Foshan, Fuzhou
2024-11-12
Recruiting
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Boehringer Ingelheim
Phase 3
1,800
Beijing, Changchun, Changsha, Changzhou Shi, Chengdu, Chongqing, Foshan, Fuzhou
2024-10-14
Recruiting
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
NCT06581432Solid Tumours
Boehringer Ingelheim
Phase 2
588
Beijing, Changsha, Hangzhou, Hefei, Nanchang, Nanjing, Shanghai, Wuhan
2024-10-11
Recruiting
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824Kidney Disease, Chronic
Boehringer Ingelheim
Phase 3
11,000
Anshan, Beijing, Changzhi, Chaoyang, Chengdu, Chifeng, Chongqing, Foshan
2024-08-30
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288Heart Failure
Boehringer Ingelheim
Phase 3
6,000
Baotou, Beijing, Changchun, Changde, Changsha, Chengdu, Chenzhou, Dalian
2024-06-17
Recruiting
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Boehringer Ingelheim
Phase 3
1,700
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Hohhot, Jiaxing
2024-05-06
Active, closed
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574Lung Cancer, Non-squamous, Non-small Cell
Boehringer Ingelheim
Phase 3
428
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Taizhou
2024-02-09
Active, closed
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
NCT04886804Neoplasm Metastasis, Non-Small Cell Lung Cancer
Boehringer Ingelheim
Phase 1
554
Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanning, Shanghai
2021-07-02
Rows per page Showing 1–24 of 24
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 24 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

19 of the 24 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 3 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 24 studies
PhaseStudiesRecruitingShare
Phase 3191679.2%
Phase 23312.5%
Observational104.2%
Phase 1104.2%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Boehringer Ingelheim2419
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.